Tirofiban combined with heparin versus heparin alone in acute coronary syndrome patients undergoing emergency PCI: A retrospective study of no-reflow and myocardial perfusion

The no-reflow phenomenon is an important complication of emergency percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS). We examined the association between adjunctive tirofiban and in-hospital angiographic and electrocardiographic reperfusion indicators. This single-center retrospective observational study included 186 ACS patients who underwent emergency PCI between January 2021 and December 2024. According to perioperative antithrombotic treatment, patients were divided into a tirofiban plus heparin group (n = 92) and a heparin-alone group (n = 94). Because treatment assignment was nonrandom and determined by the treating interventional cardiologist, the analysis was designed to estimate associations rather than causal treatment effects. For the no-reflow outcome, a parsimonious multivariable logistic regression model adjusted for clinically relevant measured confounders, including diabetes mellitus, symptom-to-balloon time > 6 hours, high thrombus burden, and pre-PCI thrombolysis in myocardial infarction (grade/flow) (TIMI) 0-1 flow. No-reflow was recorded in 8/92 (8.7%) versus 20/94 (21.3%) patients (P = .016). Final TIMI grade 3 flow occurred in 91.3% versus 79.8% (P = .028); myocardial blush grade 2-3 in 84.8% versus 68.1% (P = .008); TIMI myocardial perfusion grade 2-3 in 82.6% versus 66.0% (P = .010); and ST-segment resolution > 70% in 65.2% versus 47.9% (P = .017). The originally reported adjusted odds ratio for no-reflow associated with tirofiban was 0.36 (95% confidence interval 0.14-0.90; P = .029). Bleeding Academic Research Consortium major bleeding occurred in 3/92 (3.3%) versus 2/94 (2.1%; P = .679); Bleeding Academic Research Consortium minor bleeding in 6/92 (6.5%) versus 5/94 (5.3%; P = .733). These small event counts do not establish comparable safety. In ACS patients undergoing emergency PCI, tirofiban plus heparin was associated with a lower incidence of intraoperative no-reflow and with improved surrogate markers of epicardial and myocardial reperfusion compared with heparin alone. These findings are hypothesis-generating and require confirmation in prospective studies with standardized treatment protocols and longer-term clinical follow-up.

Authors

Institutions

Publication Details

Journal
Medicine
Published
2026-11-13
DOI
https://doi.org/10.1097/md.0000000000051503
Primary Topic
Acute Myocardial Infarction Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Tirofiban combined with heparin versus heparin alone in acute coronary syndrome patients undergoing emergency PCI: A retrospective study of no-reflow and myocardial perfusion

Zhao Luo, Yan Yang, Zhanqun Pan
Medicine
Acute Myocardial Infarction Research
article

Tirofiban combined with heparin versus heparin alone in acute coronary syndrome patients undergoing emergency PCI: A retrospective study of no-reflow and myocardial perfusion

Zhao Luo, Yan Yang, Zhanqun Pan
article en

Abstract

The no-reflow phenomenon is an important complication of emergency percutaneous coronary intervention (PCI) for acute coronary syndrome (ACS). We examined the association between adjunctive tirofiban and in-hospital angiographic and electrocardiographic reperfusion indicators. This single-center retrospective observational study included 186 ACS patients who underwent emergency PCI between January 2021 and December 2024. According to perioperative antithrombotic treatment, patients were divided into a tirofiban plus heparin group (n = 92) and a heparin-alone group (n = 94). Because treatment assignment was nonrandom and determined by the treating interventional cardiologist, the analysis was designed to estimate associations rather than causal treatment effects. For the no-reflow outcome, a parsimonious multivariable logistic regression model adjusted for clinically relevant measured confounders, including diabetes mellitus, symptom-to-balloon time > 6 hours, high thrombus burden, and pre-PCI thrombolysis in myocardial infarction (grade/flow) (TIMI) 0-1 flow. No-reflow was recorded in 8/92 (8.7%) versus 20/94 (21.3%) patients (P = .016). Final TIMI grade 3 flow occurred in 91.3% versus 79.8% (P = .028); myocardial blush grade 2-3 in 84.8% versus 68.1% (P = .008); TIMI myocardial perfusion grade 2-3 in 82.6% versus 66.0% (P = .010); and ST-segment resolution > 70% in 65.2% versus 47.9% (P = .017). The originally reported adjusted odds ratio for no-reflow associated with tirofiban was 0.36 (95% confidence interval 0.14-0.90; P = .029). Bleeding Academic Research Consortium major bleeding occurred in 3/92 (3.3%) versus 2/94 (2.1%; P = .679); Bleeding Academic Research Consortium minor bleeding in 6/92 (6.5%) versus 5/94 (5.3%; P = .733). These small event counts do not establish comparable safety. In ACS patients undergoing emergency PCI, tirofiban plus heparin was associated with a lower incidence of intraoperative no-reflow and with improved surrogate markers of epicardial and myocardial reperfusion compared with heparin alone. These findings are hypothesis-generating and require confirmation in prospective studies with standardized treatment protocols and longer-term clinical follow-up.

MedicineVol. 105(46)
China Three Gorges University (CN), Yichang Central People's Hospital (CN)
Good health and well-being
Acute Myocardial Infarction Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon